Irbesartán/Hidroclorotiazida Kern Pharma

Irbesartan/Hydrochlorothiazide, the active ingredients in Irbesartán/Hidroclorotiazida Kern Pharma, are an Angiotensin II receptor blocker (ARB) and a thiazide diuretic presented as tablets for oral use. They are prescribed to lower blood pressure in adults, often when monotherapy is insufficient. GNH USA supplies Irbesartán/Hidroclorotiazida Kern Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system and renal sodium handling to control elevated blood pressure. - Hypertension: reduces systolic and diastolic pressure in patients with essential hypertension. - Diabetic nephropathy: slows progression of kidney damage in type 2 diabetes when combined with standard care. - Hypertension requiring diuretic therapy: provides additional fluid‑excreting effect to achieve target blood pressure.

Common Side Effects: - Dizziness: transient light‑headedness, especially after the first doses. - Headache: mild to moderate intensity, often resolves with continued therapy. - Increased urination: due to the diuretic component, may be more noticeable at night. - Electrolyte changes: mild alterations in potassium or sodium levels. - Fatigue: occasional tiredness during dose titration.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Acute kidney injury: sudden decline in renal function, particularly in volume‑depleted patients. - Hyperkalemia: elevated potassium levels, especially when combined with potassium‑sparing agents. - Angioedema: swelling of face, lips, tongue, or throat requiring urgent care. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should assess patient history and monitor relevant parameters. - Blood pressure monitoring: check regularly to avoid excessive lowering. - Renal function: evaluate serum creatinine and eGFR at baseline and during treatment. - Electrolyte balance: monitor potassium and sodium, especially when using other diuretics. - Pregnancy: avoid unless clearly needed, as safety data are limited. - Concomitant medications: review for agents that may increase potassium or affect renal perfusion. - Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide can alter the effects of several drugs. Major Interactions (Avoid): - Aliskiren (in diabetes): combined use may increase risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. Moderate Interactions (Monitor Closely): - NSAIDs: can reduce antihypertensive efficacy and worsen renal function. - Lithium: may increase lithium concentrations, requiring serum level monitoring. - ACE inhibitors: concurrent use can heighten the risk of hypotension and renal dysfunction.